BVCF (BioVeda China Fund), a Shanghai-based private equity and venture investment firm focused on life sciences, is targeting US$400 million for its fourth U.S. dollar fund and is expecting a first close in a few months, according to someone familiar with the matter.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?